Comparative Pharmacology
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus MYCELEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus MYCELEX.
GYNE-LOTRIMIN 3 vs MYCELEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, thereby disrupting ergosterol biosynthesis and compromising fungal cell membrane integrity.
Intravaginal: one applicatorful (5 g of 2% cream) or one suppository (200 mg) once daily at bedtime for 3 days.
For oropharyngeal candidiasis: Clotrimazole troche 10 mg dissolved slowly in mouth 5 times daily for 14 days. For vulvovaginal candidiasis: Clotrimazole vaginal tablet 500 mg single dose or 200 mg daily for 3 days or 100 mg daily for 7 days; 1% vaginal cream 5 g intravaginally daily for 7-14 days.
None Documented
None Documented
Terminal elimination half-life is 3.5–5 hours for topical administration; systemic absorption is minimal (<0.5%), so half-life reflects local clearance.
Terminal elimination half-life is 20-50 hours (mean ~30 hours) in adults; prolonged in neonates (~40-80 hours) and in hepatic impairment.
Clotrimazole is primarily excreted via feces (biliary elimination) as metabolites, with approximately 0.5% excreted renally as unchanged drug.
Primarily hepatic metabolism; <1% excreted unchanged in urine; ~50% of dose excreted in feces as metabolites.
Category C
Category C
Azole Antifungal
Azole Antifungal